SAN FRANCISCO, Sept. 11, 2012 (GLOBE NEWSWIRE) -- ICAAC 2012 -- Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for life-threatening infections, announced today that several abstracts related to tedizolid phosphate (TR-701) are being presented at the 52 nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting in San Francisco from September 9 to September 12, 2012. A total of 12 tedizolid-related posters have been accepted for presentation, including clinical results and preclinical studies of tedizolid against gram-positive bacterial infections.
The clinical abstracts examine the effect of tedizolid in patients with acute bacterial skin and skin structure infections (ABSSSI), as well as liver- and renal-impaired, adolescent and elderly populations. The abstracts include two poster presentations from the ESTABLISH 1 trial summarizing detailed results from Trius' first Phase 3 trial (TR-701-112) of tedizolid in patients with ABSSSI. This marks the first time these data are being presented at a major medical meeting. Top-line results, reported in December 2011, showed that tedizolid achieved all primary and secondary efficacy outcomes after a short course of therapy, and showed significant improvements in key safety and tolerability measurements in the complete study population versus the comparator linezolid (Zyvox ®). This is the first of two registrational studies for tedizolid.
Tedizolid is the company's lead product candidate. It is a once daily, IV and orally administered oxazolidinone being developed for the treatment of serious gram-positive infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA)."These data add to the growing body of evidence supporting the efficacy and safety of a six-day course of once-daily oral tedizolid," said Jeff Stein, President and Chief Executive Officer at Trius Therapeutics. "We look forward to results from our second Phase 3 study of tedizolid in ABSSSI for its intravenous to oral transition therapy. These findings may offer insights into tedizolid's benefits as a patient's treatment course shifts from hospitalization to post-discharge."